These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 12441322)

  • 21. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
    Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
    Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
    Attoub S; Rivat C; Rodrigues S; Van Bocxlaer S; Bedin M; Bruyneel E; Louvet C; Kornprobst M; André T; Mareel M; Mester J; Gespach C
    Cancer Res; 2002 Sep; 62(17):4879-83. PubMed ID: 12208734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors.
    Chen H; Isozaki K; Kinoshita K; Ohashi A; Shinomura Y; Matsuzawa Y; Kitamura Y; Hirota S
    Int J Cancer; 2003 May; 105(1):130-5. PubMed ID: 12672043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
    Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma.
    Werner S; Mendoza A; Hilger RA; Erlacher M; Reichardt W; Lissat A; Konanz C; Uhl M; Niemeyer CM; Khanna C; Kontny U
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):19-31. PubMed ID: 17823799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?
    Wiedmann M; Kreth F; Feisthammel J; Deininger M; Mössner J; Caca K
    Anticancer Drugs; 2003 Oct; 14(9):751-60. PubMed ID: 14551510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Murakami T; Singh AS; Kiyuna T; Dry SM; Li Y; James AW; Igarashi K; Kawaguchi K; DeLong JC; Zhang Y; Hiroshima Y; Russell T; Eckardt MA; Yanagawa J; Federman N; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
    Oncotarget; 2016 Jul; 7(30):47556-47564. PubMed ID: 27286459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
    Frost MJ; Ferrao PT; Hughes TP; Ashman LK
    Mol Cancer Ther; 2002 Oct; 1(12):1115-24. PubMed ID: 12481435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
    Abrams TJ; Lee LB; Murray LJ; Pryer NK; Cherrington JM
    Mol Cancer Ther; 2003 May; 2(5):471-8. PubMed ID: 12748309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
    Suyama H; Igishi T; Ueda Y; Shigeoka Y; Kodani M; Morita M; Takeda K; Sumikawa T; Nakazaki H; Matsunami K; Matsumoto S; Shimizu E
    Oncol Rep; 2010 Jan; 23(1):217-22. PubMed ID: 19956885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and biological significance of hepatoma-derived growth factor in Ewing's sarcoma.
    Yang Y; Li H; Zhang F; Shi H; Zhen T; Dai S; Kang L; Liang Y; Wang J; Han A
    J Pathol; 2013 Nov; 231(3):323-34. PubMed ID: 23878072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
    Matei D; Chang DD; Jeng MH
    Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
    Yokoyama T; Miyazawa K; Yoshida T; Ohyashiki K
    Int J Oncol; 2005 Jan; 26(1):33-40. PubMed ID: 15586222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A.
    Nagano A; Ohno T; Shimizu K; Hara A; Yamamoto T; Kawai G; Saitou M; Takigami I; Matsuhashi A; Yamada K; Takei Y
    Int J Cancer; 2010 Jun; 126(12):2790-8. PubMed ID: 19642105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
    Sturla LM; Westwood G; Selby PJ; Lewis IJ; Burchill SA
    Cancer Res; 2000 Nov; 60(21):6160-70. PubMed ID: 11085540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice.
    Kamenz T; Caca K; Blüthner T; Tannapfel A; Mössner J; Wiedmann M
    World J Gastroenterol; 2006 Mar; 12(10):1583-90. PubMed ID: 16570351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.
    Heinrich MC; Griffith DJ; Druker BJ; Wait CL; Ott KA; Zigler AJ
    Blood; 2000 Aug; 96(3):925-32. PubMed ID: 10910906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.